A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

EARLY_PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions

HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

Interventions

DRUG

HB-201 IV

HB-201 given IV, one (1) time, on day 1.

DRUG

HB-201 IV

HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.

Trial Locations (1)

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee